Sun Pharmaceutical to Acquire Organon in $11.75 Billion Cash Deal

Sun Pharmaceutical Industries Limited has entered into a definitive agreement to acquire Organon & Co. in a transaction valued at an enterprise value of $11.75 billion. The deal will be executed as an all-cash purchase at $14 per share. Managing Director Kirti Ganorkar described the acquisition as a strategic move to strengthen the company's global operations. The merger is intended to position Sun Pharma as a preferred partner for the acquisition and launch of new pharmaceutical products, while integrating Organon's existing talent pool and realizing significant revenue synergies over the coming years. The acquisition is expected to close in early 2027, with funding sourced from a combination of existing cash reserves and new debt. Upon completion, the combined entity is projected to generate annual revenues of $12.4 billion. For the 2025 fiscal year, Organon reported revenue of $6.2 billion and an adjusted EBITDA of $1.9 billion. Investors reacted positively to the announcement, with Sun Pharmaceutical shares rising 7.17% to Rs 1736.60 on the National Stock Exchange. The move signals a major consolidation effort by the Indian pharmaceutical leader to scale its international presence.